The Clinical Core for the University of Pittsburgh Cancer Institute (UPCI) Lung Cancer SPORE supports the infrastructure needed to satisfy the clinical research needs of the individual SPORE translational research projects. Fulfillment of SPORE translational research aims requires access to human subjects and associated clinical outcome information and biological materials (blood and tissue). In addition, successful completion of SPORE clinical trials and other interventions requires human research conducted according to exacting standards designed to protect research subjects from research risks. The Clinical Core provides the expertise and resources needed 1) to design and complete clinical trials, 2) to recruit, characterize, and follow human subjects for translational studies of laboratory-based cancer biomarkers, and 3) to obtain blood-based and tissue-based materials in support of clinical trials and biomarker research projects. To meet these objectives, the Clinical Core articulates the following four specific aims:
Specific Aim 1 : Design and implement clinical trials and clinical studies, Specific Aim 2: Identify, solicit, and enroll subjects into SPORE clinical trials, patient registries, and high risk cohorts, Specific Aim 3: Collect, manage, and store high quality risk factor and clinical outcome information, and Specific Aim 4: Deliver protocol-directed interventions and collect blood and tissue samples. The Clinical Core designs and implements clinical trials through the active participation of experienced clinical investigators. To enroll subjects into SPORE clinical studies, the Clinical Core integrates with local lung cancer treatment programs and with the Pittsburgh Lung Screening Study (PLuSS), an established high risk cohort containing over 3600 current and ex-cigarette smokers. In the renewal period, the Clinical Core proposes serial blood and sputum collections and additional computed tomography (CT) lung cancer screenings, restricted to an extreme high risk subset (N=1000-1100) of the PLuSS High-Risk Sub-Cohort. To collect and manage research data, Clinical Core investigators receive database management support through the Biostatistical/Bioinformatics Core and organize the activities of five stable institutionally approved generic research protocols pertaining to subject recruitment, data and biological sample collection, and follow-up. To deliver interventions and collect blood and tissue samples, the Clinical Core constitutes an organized team of cancer physicians, oncology protocol nurses, and laboratory technicians supported by the SPORE Blood and Tissue Core.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA090440-09
Application #
7843719
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-05-01
Budget End
2010-04-30
Support Year
9
Fiscal Year
2009
Total Cost
$516,409
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Leng, Shuguang; Diergaarde, Brenda; Picchi, Maria A et al. (2018) Gene Promoter Hypermethylation Detected in Sputum Predicts FEV1 Decline and All-Cause Mortality in Smokers. Am J Respir Crit Care Med 198:187-196
Rothenberger, Natalie J; Somasundaram, Ashwin; Stabile, Laura P (2018) The Role of the Estrogen Pathway in the Tumor Microenvironment. Int J Mol Sci 19:
Yochum, Zachary A; Cades, Jessica; Wang, Hailun et al. (2018) Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer. Oncogene :
Stabile, Laura P; Farooqui, Mariya; Kanterewicz, Beatriz et al. (2018) Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer. J Thorac Oncol 13:399-412
Volonte, Daniela; Vyas, Avani R; Chen, Chen et al. (2018) Caveolin-1 promotes the tumor suppressor properties of oncogene-induced cellular senescence. J Biol Chem 293:1794-1809
Dandachi, Nadine; Kelly, Neil J; Wood, John P et al. (2017) Macrophage Elastase Induces TRAIL-mediated Tumor Cell Death through Its Carboxy-Terminal Domain. Am J Respir Crit Care Med 196:353-363
Chatterjee, Suman; Huang, Eric H-B; Christie, Ian et al. (2017) Reactivation of the p90RSK-CDC25C Pathway Leads to Bypass of the Ganetespib-Induced G2-M Arrest and Mediates Acquired Resistance to Ganetespib in KRAS-Mutant NSCLC. Mol Cancer Ther 16:1658-1668
Yochum, Zachary A; Cades, Jessica; Mazzacurati, Lucia et al. (2017) A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer. Mol Cancer Res 15:1764-1776
Chatterjee, Suman; Huang, Eric H-B; Christie, Ian et al. (2017) Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS-Mutant NSCLC Is Mediated via Reactivation of the ERK-p90RSK-mTOR Signaling Network. Mol Cancer Ther 16:793-804
Moiseeva, Tatiana; Hood, Brian; Schamus, Sandy et al. (2017) ATR kinase inhibition induces unscheduled origin firing through a Cdc7-dependent association between GINS and And-1. Nat Commun 8:1392

Showing the most recent 10 out of 191 publications